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Abstract 
The advent of next-generation sequencing (NGS) has revolutionized public health 
microbiology and augmented our capacity to detect current and emerging infectious 
diseases. Given the potential impact of NGS on communicable disease control, it is 
paramount to ensure standardization of 'wet' laboratory and bioinformatic protocols and 
promote comparability of methods employed by different laboratories. Therefore, one of 
the ambitious goals of the Global Microbial Identifier (GMI) initiative 
(http://www.globalmicrobialidentifier.org/) has been to establish a mechanism for inter-
laboratory NGS proficiency testing (PT). GMI Working Group 4 (WG4) has been tasked to set 
up and coordinate PT exercises. This report presents findings from the survey recently 
conducted by the WG4 among GMI members in order to ascertain NGS end-use 
requirements and attitudes towards NGS PT. The survey identified the high professional 
diversity of laboratories and individuals engaged in NGS-based public health projects and the 
wide range of capabilities within institutions, at a notable range of costs. The priority 
pathogens reported by respondents reflected the key drivers for NGS use, being the entire 
gamut of foodborne illness, with emphasis on the pathogens associated with highest disease 
burden in humans, followed by 'high profile' pathogens of clinical and public health 
importance. The performance of and participation in PT was perceived as important by most 
respondents. The wide range of sequencing and bioinformatics practices reported by end-
users highlights the importance of standardization and harmonization of NGS in public 
health and underpins the use of PT as a means to assuring quality. The findings of this survey 
will guide the design of the GMI PT program in relation to the spectrum of pathogens 
included, testing frequency and volume as well as technical requirements. The PT program 
for external quality assurance will evolve and inform the introduction of NGS into clinical and 
public health microbiology practice in the post-genomic era. 
  
  
Introduction 
The advent of next-generation sequencing (NGS) technologies has revolutionized molecular 
microbiology by making genome sequences of pathogens of clinical or public health 
importance, readily available [1]. NGS has many advantages over other existing molecular 
approaches, including throughput, quality, flexibility, scalability and thus may potentially 
replace a multitude of assays currently run simultaneously in a diagnostic microbiology 
laboratory [2,3]. 
Translation of NGS from research centers to public health and clinical laboratories has 
already begun. As the technology becomes less expensive and turnaround times shorten, 
expansion of NGS into diagnostic practice is expected to be rapid. The first significant role for 
NGS is likely to be in the communicable disease surveillance and outbreak investigations [4].  
Recent studies have demonstrated that SNPs mined from whole genome sequence (WGS) 
data [5-7] as well as gene-by-gene (core genome multi-locus sequence typing (MLST) [8]) 
comparisons provided far greater resolution for outbreak detection and for microbial strain 
tracking and trace-back for a wide range of bacterial pathogens than current gold standards 
such as pulsed-field gel electrophoresis (PFGE), spoligotyping, variable number tandem 
repeat-based typing.  Additionally, the growth of public databases harboring reference 
genomes continues to enhance the utility of NGS in public health and in clinical practice 
[9,10]. Thus NGS technologies will undoubtedly improve molecular epidemiology studies, 
public health laboratory surveillance and communicable disease control in the future [11-
13].  
This paradigm shift in clinical diagnostics and surveillance of microorganisms as a result of 
the rapid development of inexpensive NGS technologies and continuing increase in 
computing power and data-transport capacity will impact microbiology in clinical 
laboratories, hospitals and other public health institutions. Ideally, it will also enable all 
countries to detect current and emerging infectious diseases in real-time and at low cost and 
share information in a standardized manner [14]. Thus, an initiative was started in 
September 2011 by several infectious disease control centers and other organizations with 
the first meeting convened in Brussels formulating the overall goal [15]; A global system to 
aggregate, share, mine and translate genomic data for microorganisms in real-time [14]. 
Since then, the initiative has grown and is today composed by over 150 experts from around 
30 countries. Subsequently, the initiative was named; the Global Microbial Identifier (GMI) 
and a Steering Committee was established as well as five working groups.  
  
Given the expectation for a growing reliance on NGS technologies in clinical and public 
health laboratories it is paramount to assess the robustness of results to different 
methodologies in order to enhance standardization of 'wet' laboratory and bioinformatics 
analyses and promote comparability [16]. Therefore, one of the goals of the GMI initiative is 
to establish a formal mechanism for inter-laboratory test performance to ensure 
harmonization and standardization in WGS and data analysis. In February 2013 at the GMI 
initiative’s 5th meeting in Copenhagen, a visionary taskforce of scientists and other 
stakeholders met, sharing an aim of making novel genomic technologies and bioinformatics 
tools available for improved global patient diagnostics, surveillance and research, by 
developing data exchange and analysis tools for characterization of all microbial organisms 
and microbial communities.  
During this meeting, the GMI Working Group 4 (WG4) was established to coordinate the 
GMI sponsored proficiency testing (PT) exercises. By having multiple laboratories perform 
NGS on a set of well-characterized strains, the results produced by the different laboratories 
will be used to identify those steps in the process where QA/QC (quality assurance/quality 
control) measures need to be taken to increase the concordance among results and 
harmonize the interpretation of data. To ensure any PT exercise was aligned with the 
expectation of the GMI end-users, a survey to identify the types of end-user, the priority test 
organisms and quality markers to be measured was developed.  
This report outlines the results of the survey of GMI members in relation to their current 
capabilities, requirements for and attitudes towards performance of PT.  
 
  
  
  
 Methods 
With the aim to ensure harmonization and standardization in WGS and data analysis, WG4 
developed a survey using the online survey software (www.surveymonkey.com) for the 
collection of relevant information from scientists based in institutes and organizations from 
different parts of the world (appendix 1). It included questions within three main topics with 
responses allowing for: 1) identification of potential end users of a PT, 2) identification of 
target organisms to be sequenced during a PT, and 3) establishment of quality assessment 
procedures to be implemented in the PT. Differences in responses within an organization 
were likely to be observed and therefore respondents were encouraged to submit data as 
individuals/research groups within institutions. The respondents were encouraged to submit 
information on their needs and capacity in relation to DNA preparation, sequencing, and 
analysis (e.g. variant detection and clustering) enabling the organizers to take this 
information into consideration when creating the PT and in the work towards standardized 
testing and quality assurance of these tests. 
The questionnaire contained 35 items, provided in three sections, including information on 
end-users (personal and organizational information), characterization of target organisms 
and quality assessment. Specifically, information was sought regarding the institutional 
profile of respondents, capability and capacity of performing NGS, institutional priorities for 
NGS, attitudes towards a PT for NGS, operational aspects of delivering a PT for NGS and 
finally a survey of current technical NGS and bioinformatics practices. The responses were 
collected as free text or single options from pre-defined drop-down lists. Some responses 
were measured on a 5-point Likert-type scale with anchors specific to the question (e.g., 
1=strongly agree; 2=agree; 3=unsure; 4=disagree; 5=strongly disagree). Pilot testing was 
done with WG4 members to determine the acceptability and clarity of the questionnaire. 
The questionnaire is available as an appendix to this report. 
Invitations to participate in the survey were sent to members of the Global Microbial 
Identifier initiative worldwide (N=155) with a link directing to the online survey. No 
monetary incentive was offered. The invitation included information that responses would 
be kept confidential and would be anonymized prior to inclusion in a published report. The 
survey was available online for a two month period during which electronic invitations and 
reminders were sent to those who had not responded. Respondents were invited to send 
any questions or feedback for the survey to the organizers. Data were collected by 
  
www.surveymonkey.com and responses were downloaded both as summaries and detailed 
Excel spreadsheets.  
  
  
Results 
1. Profile of respondents (Q1-Q4) 
In all, 47 responses were registered in the system. Following de-duplication, 45 responses 
were eligible for analysis, representing an overall survey response rate of 29%. The 
distribution of respondent's country of origin was as following: United States  (n = 14, 
31.1%), United Kingdom (n = 7, 15.6%), Denmark  (n = 4, 8.9%), Canada (n = 4, 8.9%), 
Germany  (n = 3, 6.7%), France, Malaysia, Italy and Sweden (n = 2, 4.4%) and Spain, Israel, 
Poland, Finland and Australia (n = 1, 2.2%). The 45 respondents represented 39 
organizations; one institution was represented by three respondents, four institutions were 
represented by two respondents and 34 institutions by a single respondent.  
Survey respondents represented the following sectors (multi-sectoral designation was 
allowed): governmental  (n = 26, 58%), public health  (n = 25, 56%), research  (n = 24, 53%), 
university  (n = 12, 26.7%), food  (n = 11, 24.4%), animal (n = 8, 17.8%), private ownership  (n 
= 7, 15.5%), and plant / environment  (n = 5, 11.1%). The reported roles of respondents 
within their institutions (multiple roles were allowed) included: academic / researcher  (n = 
27, 60%), laboratory scientist / microbiologist  (n = 15, 33.3%), bioinformatician  (n = 13, 
28.9%), public health professional / epidemiologist  (n = 10, 22.2%), clinician (n = 3, 6.7%) 
and infection control practitioner (n = 1, 2.2%). Notably, two respondents identified 
themselves as post-graduate students (4.4%). Three respondents were representatives of 
commercial sequencing companies (6.7%) and were excluded from further analysis, which 
thus included 42 respondents in total.  
2. Capability and capacity (Q5-Q6, Q9-Q10) 
The majority of respondents had appropriate arrangements in place for shipping 
microorganisms or DNA (85.7% and 95.2%, respectively) while 64.3% had arrangements for 
genomic data transfer (Figure 1).   
All but one respondent were currently performing NGS and bioinformatics analysis. Internal 
NGS capability was reported by 84% whereas external access to NGS was reported by 57% 
(Figure 2A). Only 14% of respondents were solely dependent upon external NGS services. 
With regard to bioinformatics, 88% had internal capability whereas only 10% were solely 
dependent upon external services (Figure 2B).  
 
  
Figure 1. Organism and data transfer arrangements in place (Q5) 
  
Figure 2A. NGS capability of participating institutions (Q6) 
 
 
 
  
Figure 2B. Bioinformatics capability of participating institutions (Q6) 
   
Forty respondents reported having access to the currently available NGS technologies, 
consisting of a total of 152 different NGS platforms cumulatively reported. The distribution 
across NGS technologies is depicted in Figure 3.  
Figure 3. Distribution of NGS access across technologies 
 
  
Accessibility to different platforms internally or externally is shown in the Table 1. The three 
most commonly accessible platforms were MiSeq (23.7%), Ion torrent PGM (15%) and HiSeq 
2500 (10.5%). These three platforms accounted for 60.8% of internally accessible sequencers 
and 30.1% of externally accessible sequencers.   
Table 1. Access to NGS platforms as internal or external infrastructure (Q9). 
NGS Platform 
Number having 
any access 
Accessible 
internally 
Accessible 
externally 
Ion Torrent PGM 23 15 5 
Ion Torrent Proton 6 2 3 
GS Junior System (454) 9 5 4 
Genome Sequencer FLX (454) 12 8 4 
PacBio RS 8 3 5 
PacBio RS II 7 3 4 
HiScanSQ 3 0 2 
HiSeq 1000 4 1 3 
HISeq 1500 3 1 2 
HiSeq 2000 9 2 7 
HiSeq 2500 16 5 8 
Genome Analyzer lIx 9 4 4 
MiSeq Benchtop Sequencer 36 25 6 
ABI SOLiD 6 0 5 
other 1 0 1 
Total 152 74 63 
 
Out of 44 NGS platforms available in participating institutions and specifically intended by 
respondents for use during a PT for NGS, Illumina MiSeq, Ion Torrent PGM and HiSeq 2500 
accounted together for 81.8% of instances (24, 9 and 3 out of 44, respectively). The 
remaining were older HiSeq models (3), PacBio (3), GS 454 FLX (1) and Ion torrent proton (1).  
Any information regarding the costs of running NGS using different platforms was provided 
by 33 out of 42 respondents (78.6%). The reported costs of sequencing a single bacterial 
genome of 5MB at coverage 20X and maximum multiplexing were as shown in Table 2. In 
the majority of cases (57 out of 75, 76%), sequencing of a single bacterial genome was 
  
reported to cost less than US$ 500. At this cost, sequencing was achieved internally in 48 of 
59 platforms (81.3%) as opposing to 9 of 16 platforms externally (56.2%, p=0.1).      
Table 2. Costs of bacterial NGS by platform as reported by respondents (Q10)  
Sequencing platform <US$ 100 US$ 101-500 US$ 501-1000 >US$ 1000 
Ion Torrent PGM internal 0 11 0 0 
Ion Torrent PGM external 1 1 0 0 
Ion Torrent Proton No data provided 
GS Junior System (454) No data provided 
GS FLX (454) internal 0 0 2 2 
GS FLX (454) external 0 0 0 1 
PacBio RS internal 0 0 3 1 
PacBio RS external 0 0 0 1 
PacBio RS II internal 0 2 2 0 
HiScanSQ external 1 0 0 1 
HiSeq 1000 external 0 0 0 1 
HiSeq 1500 No data provided 
HiSeq 2000 internal 1 2 0 0 
HiSeq 2000 external 0 1 1 0 
HiSeq 2500 internal 4 3 0 0 
HiSeq 2500 external 1 0 0 1 
GA IIx internal 1 2 0 0 
MiSeq Benchtop internal 9 13 1 0 
MiSeq Benchtop external 1 3 0 1 
ABI SOLiD No data provided 
Other No data provided 
Total internal 15 33 8 3 
Total external 4 5 1 6 
Grand total 19 (25.3%) 38 (50.7%)  9 (12%) 9 (12%) 
 
 
  
The volume of NGS for bacterial genomes performed annually by respondents is 
summarized in Table 3. Of 70 NGS 'jobs' reported, 5.7% involved up to 10 genomes and 8.6% 
over 2,000 genomes. Volume of up to a 100 genomes per year accounted for 75% of 
external sequencing jobs but only 24.1% of internal sequencing jobs (p<0.005, OR=9.46). 
Sequencing by Illumina technology accounted for 13 / 25 (52%) of jobs involving up to 100 
genomes and 31 / 45 (68.9%) of experiments involving over 100 genomes (p=0.16). 
Nevertheless, 100% of the 23 NGS ‘jobs’ involving >500 genomes were performed using 
Illumina technology.    
Table 3. Volume of bacterial NGS performed annually by respondents (Q10) 
Sequencing 
platform 
1-10 11-100 101-500 501-2,000 >2,000 
Ion Torrent PGM 
internal 
0 3 6 0 0 
Ion Torrent PGM 
external 
2 1 0 0 0 
Ion Torrent Proton No data provided 
GS Junior (454) No data provided 
GS FLX (454) 
internal 
0 0 1 0 0 
GS FLX (454) 
external 
0 0 0 0 0 
PacBio RS internal 0 2 2 0 0 
PacBio RS external 0 1 0 0 0 
PacBio RS II 
internal 
0 3 1 0 0 
HiScanSQ external 0 0 1 0 0 
HiSeq 1000 
external 
0 1 0 0 0 
HiSeq 1500 No data provided 
HiSeq 2000 
internal 
0 1 0 2 0 
HiSeq 2000 
external 
0 2 0 0 1 
  
HiSeq 2500 
internal 
0 0 1 3 3 
HiSeq 2500 
external 
0 1 0 0 0 
GA IIx internal 1 0 0 2 0 
MiSeq Benchtop 
internal 
1 2 9 10 1 
MiSeq Benchtop 
external 
0 4 1 0 1 
ABI SOLiD No data provided 
Other No data provided 
Total internal 2 11 20 17 4 
Total external 2 10 2 0 2 
Grand total 4 (5.7%) 21 (30%) 22 (31.4%) 17 (24.3%) 6 (8.6%) 
 
3. Sequencing priorities (Q11-Q16) 
Information regarding priority pathogens most frequently processed by participating 
institutions was provided by 34 of 42 respondents. For five categories allowed, a total of 142 
pathogens were listed (34 respondents listed at least one category of the most frequently 
processed pathogen while 23 listed all five priority categories). The taxon distribution of the 
first category appears in Figure 4A. Notably, three out four pathogens most frequently 
sequenced were foodborne pathogens (Figure 4B).  
 
 
 
 
 
 
 
  
Figure 4A. Distribution of top priority pathogens most commonly processed in 
participating institutions (Q11)  
 
 
Figure 4B. Distribution of pathogens most commonly processed in participating 
institutions  
 
  
The frequency of taxon sequenced over the passing year by respondents is shown in Figure 
4C. Top 5 sequenced pathogens were again the leading foodborne pathogens and S. aureus.  
Figure 4C. Frequency of taxons genome sequenced over passing year. (Q12) 
 
 
The reasons for using NGS were reported by 41 respondents, according to 11 provided 
application categories using a 1-5 scale (1 – most important, 5 - least important). The 
average scores for the 11 categories are shown in Figure 5A. The leading indication was by 
far high resolution clustering for outbreak investigation (mean score 1.6) whereas 
metagenomics, pathogen discovery and evolutionary microbiology were perceived as least 
important (mean scores >3 points).  
The consideration in selecting pathogens for using NGS were reported by 41 respondents, 
according to 9 provided application categories using a 1-5 scale (1 – most important, 5 - least 
important). The average scores for the 11 categories are shown in Figure 5B. The leading 
consideration was by far a high impact on public health (mean score 1.69) followed by utility 
for performing real time laboratory surveillance (mean score 2.32).  
  
  
Figure 5A. Main purpose of NGS experiments (mean scores). (Q13) 
  
Figure 5B. Criteria for selecting pathogens for NGS experiments (mean scores) (Q15). 
 
 
 
  
4. Attitudes towards proficiency testing for NGS (Q17) 
None of the 41 respondents strongly disagreed with any of the nine statements concerning 
the evaluation criteria for PT for NGS. Over 75% of respondents expressed agreement or 
strong agreement with all nine statements. In particular, accurate classification of existing 
frequently tested and globally relevant pathogens (e.g., foodborne Salmonella) as well as 
phylogenetic tree building were statements with which >90% agreed or strongly agreed. Any 
disagreement was noted in six out of the nine statements but at a rate below 10%. 
Table 4. Agreement with possible evaluation criteria of PT for NGS (Q17) 
Statement Strong disagreement                 Strong agreement % agreement 
17.1 Assessment of the 
quality of WGS reads is a very 
important consideration 
0 2 4 15 20 85.4% 
17.2 Ability to integrate and 
accommodate sequence data 
from multiple vendor 
platforms is a very important 
consideration 
0 2 4 17 18 85.4% 
17.3 Capacity for de novo 
sequencing and genome 
assembly is a very important 
consideration 
0 3 6 21 11 78% 
17.4 Capacity for analysis of 
emerging biothreats is a very 
important consideration 
0 0 11 19 11 73.2% 
17.5 Accurate classification of 
existing frequently tested and 
globally relevant pathogens 
(e.g., foodborne Salmonella) is 
a very important 
consideration 
0 0 3 22 16 92.7% 
17.6 Quality of reference 
based assembly is a very 
important consideration 
0 3 6 20 12 78% 
17.7 Quality of annotation is a 
very important consideration 
0 2 8 24 7 75.6% 
17.8 Single nucleotide 
polymorphism (SNP) calls is a 
very important consideration 
0 2 4 15 20 85.4% 
17.9 Tree building is a very 
important consideration 
0 0 4 24 13 90.2% 
  
5. Operational aspects of PT for NGS (Q18-Q20) 
Respondents were asked to delineate five priority pathogens for inclusion in the PT for NGS 
that will look at all stages of sequencing and analysis processes. Based on 24 respondents 
providing this information, Salmonella was by far the top priority for NGS PT, listed by 9 
respondents, followed by S. aureus and RNA viruses (3 each), L. monocytogenes, M. 
tuberculosis and E. coli (2 each) and influenza virus, Campylobacter spp. and C. difficile, (1 
each). When prioritization was generated after pooling all five priority categories reported 
(Figure 6A), the leading pathogens were Salmonella (17%), E. coli (14%) and Campylobacter 
spp. (12%), followed by S. aureus (9%) and L. monocytogenes (8%).     
Figure 6A. Priority pathogens for inclusion in PT for NGS sequencing (Q18) 
 
Respondents were also asked to delineate five priority pathogens for inclusion in a PT for 
NGS carried out by provision of simulated datasets for bioinformatics analysis. Based on 26 
respondents providing this information, Salmonella was again the top priority for NGS PT, 
listed by 9 respondents, followed by S. aureus (4), E. coli (3), RNA viruses, L. monocytogenes, 
M. tuberculosis and Enterobacteriaceae (2 each) and influenza virus and Campylobacter spp. 
(1 each). When prioritization was generated after pooling all five priority categories (Figure 
6B), the leading pathogens were E. coli, Salmonella and Campylobacter spp. followed by L. 
monocytogenes, M. tuberculosis and S. aureus.     
  
Figure 6B. Priority pathogens for inclusion in PT for NGS bioinformatics analysis (Q19). 
 
With regards to the number of different strains to be used in the PT, per dispatch, 36 
respondents displayed the following preferences (Table 5): 39.4%, 57.6% and 53.1% of 
respondents regarded PT samples containing viruses, fungi and protozoa as not relevant, as 
compared to only 8.3% for bacterial PT. A substantial proportion of respondents were willing 
to process 4 bacterial PT samples per dispatch (44.4% for strains, 47.2% for DNA and 50% for 
genomic datasets). Of those interested in viral PT, 60% were willing to process 4 samples per 
dispatch.   
Table 5. Preferred number of strains per dispatch of PT for NGS (Q20). 
PT sample type 1 2 3 4 N/A 
24.1 Microorganisms (bacterial) for DNA purification 
and sequencing 
4 4 9 16 3 
24.2 Microorganisms (viral) for DNA purification and 
sequencing 
2 2 4 12 13 
24.3 Microorganisms (fungal) for DNA purification and 
sequencing 
4 1 5 4 19 
24.4 Microorganisms (protozoan) for DNA purification 
and sequencing 
4 4 3 4 17 
24.5 Samples of DNA for sequencing 2 6 6 17 5 
24.6 Datasets from NGS platforms for data analysis 2 3 9 18 4 
N/A – not applicable 
  
6. NGS and bioinformatics practices (Q21-Q35) 
The survey of current technical NGS and bioinformatics practices and usage included a series 
of 15 questionnaire items with a varying response rate. The intended use of NGS data were 
reported by 39 respondents and is shown in Figure 7. 
Figure 7. Intended use of NGS data (Q21). 
 
 
NGS was used commonly for de novo sequencing, resequencing, metagenomics and RNA 
sequencing. Two respondents highlighted data would be used to create public health policy 
or develop bioinformatics tools. 
For library preparation, a notable diversity in methods used was reported among 39 
respondents with transposon-based fragmentation being the most common method, 
followed by physical shearing and enzymatic shearing (Figure 8). In addition, 74.3% reported 
multiplexing of samples in NGS runs was being performed. Notably, 29% reported not to be 
performing hands-on library preparation. 
  
  
Figure 8. Library preparation methods employed for NGS (Q22) 
 
Importantly, only 46.7% of respondents (35.9% overall) were routinely including standard or 
reference materials in their NGS runs. 
The commonly expected coverage while performing NGS for bacteria was 31-60X (51.3% of 
respondents) and coverage of 11-30X or over 60X was reported by 21.6% and 18.9%, 
respectively (Table 6). Of those performing NGS for viruses, 12 out of 17 (76%) were working 
at coverage of >60X. Very few were performing practical NGS for fungi and protozoa, with 
results varying. 
Table 6. Expected coverage while performing NGS for various taxa (Q24) 
 less than 10 11-30 31-60 over 60 
Not 
applicable 
Bacteria 1 8 19 7 2 
Virus 0 3 2 12 14 
Fungus 0 5 1 1 23 
Protozoa 1 4 0 3 21 
 
The genomic information intended to be captured from NGS data analysis was diverse 
(Figure 9). Single nucleotide polymorphisms (SNPs) and locus-specific variations were the 
most commonly expected outputs of NGS analysis (90% and 85%, respectively), followed by 
mobile genetic elements and insertions/deletions (indels) (77.5% each).  
 
  
Figure 9. Genomic information intended to be captured from NGS (Q26). 
 
Of 29 respondents, 86.2% reported low-quality base trimming during bioinformatics 
analysis. Those few not performing trimming reported it was either not necessary for their 
intended use, performed automatically by their NGS software or will consider trimming in 
future analyses. 
The vast majority of respondents perceived quality filtering as important to any extent (92%) 
and 56% very important (Figure 10). In addition, of 34 respondents performing assemblies of 
NGS data, 73.5% reported having any established criteria for quality assessment and quality 
control of assemblies. Most of the 25 respondents reporting having quality criteria for 
assemblies in place employed more than one criterion. The frequency of various criteria is 
shown on Figure 11. The most commonly used criterion was coverage (90.9%) followed by 
number of bases and mapping of reads to reference (68.2% each). When respondents were 
asked to provide values for quality criteria, a wide variety of responses was noted and no 
conclusions could be drawn. 
 
  
Figure 10. Perception of the importance of quality filtering during NGS analysis (Q28) 
     
Figure 11. Frequency of criteria used for QA/QC of assemblies 
 
 
  
The use of bioinformatics software is shown in Figure 12. Of 35 respondents, 71% stated 
they used mainly or exclusively externally developed software whereas 23% relied mainly 
but not exclusively on internally developed software. In 6% analyses were done elsewhere. 
Of those 35, 32 respondents also provided information regarding specific assembly software 
being used. The leading software was Velvet (75%), Newbler (46.9%) and CLC (46.9%) and 
SOAPdenovo (25%). Other software used by less than 20% of users included ABySS, 
ALLPATHS-LG, CABOG, Edena, Euler, Mira, MSR-CA, SGA, SSAKE, VCAKE, SPAdes, Cortex, 
CloVR, RAST, Geneious and SAMtools.  
Thirty respondents provided information regarding specific mapping software packages 
being used. The leading software was BWA (66.7%), Bowtie 2 (53.3%) and Bowtie 1 (23.3%). 
Other software used by 10% of users included Novoalign and SMALT, while BFAST, MAQ, 
SHRiMP, SSAHA2, tmap and Geneious were used by less than 10%.  
Figure 12. Use of bioinformatics software for analysis(Q32) 
 
  
  
Discussion 
The WGS data is worth more if it is shared globally in an open source manner and linked to 
clinical and epidemiological contexts (e.g., informative metadata). Notably, pioneering 
studies to inform implementation of NGS based real-time prospective surveillance and 
analysis of foodborne pathogens such as Listeria monocytogenes and Salmonella enterica 
are underway in leading institutions throughout North America and Europe. Moreover, the 
use of NGS for near real-time investigation of probable transmission pathways has already 
been reported [6,17-19]. 
As WGS is applied to public health surveillance, standardizing quality metrics becomes 
critical. These metrics include, for example, standards for calibration, validation, and 
comparison among platforms; data reliability, robustness, and reproducibility, and the 
quality of assemblers [3,16]. Like any technology, WGS has its advantages and limitations. 
Potential uncertainties and errors can be introduced into the sequence analysis by the 
sequencing machines, analytical algorithms and residual errors in the reference data with 
what we align the new sequence. Thus proficiency testing programs that cover both 
sequencing “wet lab” and analytical “dry lab” steps are urgently required. To our knowledge, 
this is the first review of needs and priorities in relation to the proficiency testing for WGS 
performed in the field of microbiology. 
Key findings 
The current report illustrates current NGS and bioinformatics capability and practice within 
the GMI community and attitudes towards the setting up and delivery of a PT program for 
NGS. Our survey highlights the professional diversity of individuals engaged in NGS-based 
projects and the wide range of capabilities within institutions. For example, some 
institutions are currently performing NGS on a limited basis, mainly by relying on external 
sequencing and analysis services, while other institutions are running large scale NGS studies 
with internal sequencing and computational infrastructures. This diversity is also associated 
with a notable range of costs per sample. 
The priority pathogens reported by respondents that are being investigated with NGS 
represent the entire gamut of foodborne illness, with emphasis on the pathogens associated 
with highest disease burden in humans, followed by 'high profile' non-foodborne pathogens 
of clinical and public health importance such as M. tuberculosis, S. aureus and RNA viruses. 
  
This is in agreement with the fact that key outputs expected from NGS are of use in 
molecular epidemiology, high resolution typing and outbreak investigation. 
For most end-users, the performance of and participation in PT was perceived as important. 
Information collated through this survey will help guide the PT in terms of the pathogens 
included, PT frequency and technical requirements. The wide range of sequencing and 
bioinformatics practices reported by end-users highlights the importance of standardization 
and harmonization of NGS in public health and underpins the use of PT as a means to 
assuring quality. 
Quality consideration for NGS in microbiology 
There are significant differences in the sequencing methods, specimen preparation, run 
throughput and hands-on time between different sequencing platforms. In addition, the 
amount of sequencing data sufficient for pathogen characterization (i.e. genome ‘coverage’) 
and associated outbreak investigations remains the subject of debate [1,20]. These variables 
may have technology- and coverage-specific effects on the detection of genomic variants. 
Thus laboratories are expected to balance the pathogen genome characteristics, the 
instrument throughput, the accuracy of variant-calling algorithms and the cost of sequencing 
runs.  
The outputs generated by different sequencing platforms are subjected to multiple 
analytical steps that usually start with sequence assembly or reference-based mapping and 
finish with simultaneous comparisons of multiple genomes and data visualization. 
Bioinformatic approaches for genome-wide analyses of pathogens are highly varied across 
the microbiology community, with an abundance of tools continually being developed, 
refined and packaged together as software ‘pipelines’ [21].  
While NGS based surveillance is expected to become common in the near term [3], 
identification of pathogens, rather than traceback investigations, is likely to be among the 
last areas where NGS becomes routine as the cost are high and other technologies such as 
qPCR and MALDI-TOF are effective. However, the technology could be employed to detect 
yet unknown, emerging or fastidious pathogens. Furthermore, deep sequencing would allow 
in the near future, identification of pathogens from primary clinical samples and/or to 
characterize the normal microbiota and pathogenic flora of non-sterile body sites using 
meta-genomic strategies. 
 
  
Impact of survey outputs on envisaged PT for NGS 
Principles of NGS standardization for clinical testing have been recently outlined by a 
national working group on laboratory medicine convened by the US Centers for Disease 
Control and Prevention [16]. Their recommendations emphasize the need for adequate 
validation, quality control, use of reference materials and performance of independent PT. 
In agreement with such recommendations, GMI is currently executing a pilot PT scheme 
with intended full roll-out in ultimo 2014. The main objective of this PT is to ensure 
harmonization and standardization in whole genome sequencing and data analysis, with the 
aim to produce comparable data for the GMI initiative. A further objective is to assess and 
improve the uploaded data to databases such as NCBI, EBI and DDBJ. Therefore, the 
laboratory work analysis performed for this PT should be done by using the methods 
routinely used in the individual laboratories.  
The PT will consist of two wet-lab and one dry-lab component(s) targeting priority 
microorganisms such as Salmonella, E. coli and S. aureus. The wet-lab components provided, 
will assess the laboratories ability to perform DNA preparation, sequencing procedures and 
analysis of epidemiological markers whereas the dry component will assess the 
laboratories' ability to analyse a whole-genome-sequencing dataset and distinguish between 
clonally related and sporadic genomes. In order to achieve this, the PT substrates will be 
provided to participants via transport of lyophilized live cultures and stabilized bacterial DNA 
distributed by courier and electronic fastq datasets provided through ftp servers. 
Study limitation 
These conclusions should be interpreted in light of the limitations in the study design. First, 
the survey relied on self-reported behavior without verification that participants actually 
practiced in the manner described. Second, we surveyed only GMI participants. Scientists in 
the developing world are likely to differ from developed world practitioners in their 
technology use and in information needs. However, this has the advantage of representing 
the point of view of professionals who are usually “early adopters” of new concepts and the 
opinion leaders in their field. Third, there may be a volunteer bias related to the fact the 
those community member being more advanced in NGS implementation or having increased 
interest in moving into NGS were more likely to sign up to the survey.  
 
 
  
Conclusion – the way forward  
The significant variation in the use of NGS and data analytics in public health microbiology 
and differences in attitudes of microbiologists deserve careful consideration. Important for 
the reliability of submitted sequence data to a GMI database and other public sequence 
archives will be the test of the congruence among members’ in DNA extraction, library 
preparation, the actual sequencing, assembly and phylogenetic analysis following different 
laboratory protocols, software tools, and platforms [16,21]. GMI aims to assist laboratories 
and partners globally to perform NGS to the highest degree of quality. The findings of our 
survey will guide the PT activities of the GMI to ensure it meets the expectations of the end-
users. In addition we have gathered information on capability, attitudes and practices of 
GMI community members.  
It is envisaged that PT of WGS in microbiology will be a dynamic process that will 
continuously evolve and, thereby, inform the introduction of NGS into clinical and public 
health microbiology practice and will inevitably become the routine tool for external quality 
assurance in the post-genomic era.  
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